Moving data analytics upstream to design phase could bring huge savings, claims clinical development KOL

4 March 2020

“The cost of having to amend your Phase III trial for eligibility criteria has been estimated at about half a million dollars, or for a Phase II trial, it’s roughly $140,000.”

Those are the words of Rob DiCicco, deputy chief health officer, IBM Watson Health, who has spent 25 years working in clinical development with GlaxoSmithKline (LSE: GSK) and other companies, becoming a respected key opinion leader (KOL) in the area.

He has done a lot of work with TransCelerate BioPharma, a non-profit that collaborates across the biopharmaceutical research and development community to help find efficiencies in the highly expensive process of delivering new medicines.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK